Session 1.
(Sunday PM) | Defining the need for new antituberculars |
Discussion Leader: Ariel Pablos-Mendez (The Rockefeller Foundation, NY, USA)
- Chris Dye (World Health Organization, Geneva, Switzerland)
"The global epidemiology of tuberculosis, and the potential impact of new drugs"
- Rick O'Brien (Centers for Disease Control, Atlanta, USA)
"The need for new TB drugs: obstacles and opportunities"
Session 2.
(Monday AM) | Target Selection & Rational Design |
Discussion Leader: Ken Duncan (GlaxoSmithKline, UK)
- Patrick Brennan (Colorado State University, Ft. Collins, USA)
"A Multi-Institutional TB Drug Discovery Program Based on Fundamental Principles of Mycobacterium tuberculosis Cell Wall Biosynthesis"
- James Sacchettini (Texas A&M University, USA)
"Structure-based design of drugs that target enzymes in fatty acid synthesis and degradation"
- John Blanchard (AECOM, USA)
"Enzymes of Mycobacterial Amino acid and Cofactor Biosynthesis as Potential Targets."
- Issar Smith (Public Health Research Institute, NY)
"Mycobacterium tuberculosis interactions with host macrophages"
Session 3.
(Monday PM) | Clinical Issues in the Evaluation of New Antituberculars |
Discussion Leader: Bernard Fourie (MRC, South Africa)
- Kathy Eisenach (University of Arkansas, Little Rock, AK, USA)
"The use of surrogate markers of drug efficacy in the clinical evaluation of novel antimycobacterial agents"
- Charles Peloquin (National Jewish Hospital, Denver, USA)
"TB Drug Delivery and Drug Interactions"
- Robert Wallace (UMDNJ Med School, NJ)
"A whole blood bactericidal assay for tuberculosis"
Session 4.
(Tuesday AM) | Screening and Lead Compound Identification |
Discussion Leader: John Lonsdale (GlaxoSmithKline, US)
- Martin Everett (GlaxoSmithKline, UK)
"Target development and lead identification."
- Denis Mitchison (St. George's Hospital Medical School, London)
"Selection for sterilising activity"
- Barbara Laughon (NIAID, USA)
"NIAID screening resources for drug discovery"
- Richard Lee (University of Tennessee, Memphis)
"Synthesis and evaluation of diamine libraries as new tuberculosis chemotherapies"
Session 5.
(Tuesday PM) | Latency and TB Drug Development |
Discussion Leader: Ken Stover (PathoGenesis/Chiron, USA)
- David Russell (Cornell University, USA)
"Plumbing the environment within the infected phagocyte"
- Joanne Flynn (University of Pittsburgh, USA)
"The challenges of using animal models to study latent tuberculosis"
- Galina Mukamolova (Bach Institute of Biochemistry, Moscow)
"Rpg-like growth factors from mycobacterium tuberculosis"
Session 6.
(Wednesday AM) | Animal Models for Assessing Drug Efficacy |
Discussion Leader: David McMurray (Texas A&M University, USA)
- Jacques Grosset (Groupe Hospitalier Pitie-Salpetriere, Paris)
"Compared with the standard first line antituberculosis drugs-rifampin, isoniazid, pyrazinamide, streptomycin, ethambutol-, which new drugs have in the mouse model a promising efficacy?"
- Ian Orme (Colorado State University, Ft. Collins, USA)
"Aerosol infection models for testing drugs in vivo"
- Bala Subramanian (AstraZeneca, India)
"Efficacy of Anti-TB Compounds:A Pre-Clinical R&D Experience"
- Anthony Hickey (UNC, Chapel Hill)
"Aerosol delivery of drugs to the lungs: implications for tuberculosis therapy"
Session 7.
(Wednesday PM) | Drug Resistance Mechanisms |
Discussion Leader: Clif Barry (NIH)
- Valerie Mizrahi (South African Instit. Med. Res., Johannesburg, RSA)
"Acids and fatty acids: Relevance to the mode of action of pyrazinamide"
- William R. Jacobs, Jr. (AECOM, USA)
"The mechanism of action of isoniazid: A proverb of blind men and an elephant."
- Peter Tonge (SUNY Stony Brook)
"Mechanism of action of isoniazid"
Session 8.
(Thursday AM) | Medicinal Chemistry |
Discussion Leader: Michael Hearn (Wellsley College, USA)
- Paul Wyatt (GlaxoSmithKline, UK)
"Thiolactomycin: the rocky road from lead to clinical candidate"
- John Welch (SUNY, Albany, USA)
"Chemical Modification of Pyrazinamide; A Tool for New Insights into an Old Drug."
- Stephen Gillespie (Royal Free, London)
"Engineering molecules to solve clinical problems."
- Ramesh Panchagnula (NIPER, India)
"Rifampicin: revisited"
Session 9.
(Thursday PM) | Emerging Genome-Scale Tools for Drug Discovery |
Discussion Leader: Stewart Cole (Institute Pasteur, Paris)
- Mike Wilson (NIAID, RTB, USA)
"Microarray platforms and tactics for analyzing gene expression profiles"
- Ruth McAdam (GlaxoSmithKline, UK)
"Saturation transposon mutagenesis and proteomics to prioritize therapeutic targets in TB"
- Ted Baker (Auckland, New Zealand)
"From ORFs to protein structures to drugs: a consortium approach to the structural genomics of TB"
- Calvin Boon (Institute of Molecular and Cell Biology, Singapore)
"Proteins of mycobacterium bovis BCG induced in the Wayne Dormancy Model"
|
